Vaccination with recombinant RgpA peptide protects against Porphyromonas gingivalis-induced bone loss

Area of Science:

• Periodontology
• Immunology
• Microbiology

Background:

• Porphyromonas gingivalis infection is a primary cause of periodontitis.
• Understanding early immune responses is crucial for developing effective treatments.

Purpose of the Study:

• To evaluate the efficacy of RgpA vaccination in modulating immune responses and preventing bone loss.
• To investigate the anti-inflammatory potential of native and recombinant RgpA.

Main Methods:

• Utilized a subcutaneous chamber model to analyze cytokine profiles in response to native RgpA.
• Administered recombinant RgpA to mice infected with P. gingivalis and assessed serum antibody titers and bone resorption.

Main Results:

• Native RgpA immunization promoted an anti-inflammatory local response by decreasing IL-1β and increasing IL-4.
• Recombinant RgpA vaccination significantly reduced periodontal bone loss by 50% and induced a Th2-biased humoral response (high IgG1/low IgG2a).

Conclusions:

• RgpA vaccination holds potential for shifting early immune responses towards an anti-inflammatory profile.
• Vaccination with recombinant RgpA offers protection against P. gingivalis-induced periodontitis.